Tesamorelin

Tesamorelin Peptide

Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipid metabolism, but has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury.

Specifications

Tesamorelin Research

What is tesamorelin peptide used for?

Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy.

Does tesamorelin increase muscle mass?

Conclusions: Among those with clinically significant decrease in visceral adipose tissue on treatment, tesamorelin was effective in increasing skeletal muscle area and density.

How long does it take for tesamorelin to start working?

Studies showed that people being treated with Egrifta SV (tesamorelin) had lower belly fat after 26 weeks of treatment compared with people who weren't receiving the medication. If you've been on Egrifta SV (tesamorelin) for 26 weeks and haven't noticed a change in your belly fat, talk to your healthcare provider.

How often do you inject tesamorelin?

Inject this medication under the skin on your stomach (abdomen) as directed by your doctor, usually once daily. To help you remember, use it at the same time each day. Pick an injection site that is below your belly button to the left or right. Avoid any area with scar tissue, bruises, reddening, or irritation.

How effective is tesamorelin?

Conclusions: Tesamorelin reduces visceral fat by approximately 18% and improves body image distress in HIV-infected patients with central fat accumulation. These changes are achieved without significant side effects or perturbation of glucose.

Do you need a prescription for tesamorelin?

It is used to reduce excess fat (lipodystrophy) in the abdomen or stomach in patients infected with human immunodeficiency virus (HIV). This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Powder for Solution.

What peptides increase testosterone levels?

MK-677, known for its growth hormone-releasing effects, may increase testosterone through the elevation of insulin-like growth factor 1 (IGF-1). Ipamorelin, another growth hormone-releasing peptide, stimulates growth hormone production and IGF-1, supporting testosterone production.

References

1.Guaraldi  G, Squillace  N, Stentarelli  C,  et al.  Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.  Clin Infect Dis. 2008;47(2):250-257.

2.Hadigan  C, Liebau  J, Andersen  R, Holalkere  NS,

Sahani  DV.  Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection.  J Acquir Immune Defic Syndr. 2007;46(3):312-317.

3.Perseghin  G.  Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis.  Diabetes Care. 2011;34(suppl 2):S367-S370.

4.Crum-Cianflone  N, Dilay  A, Collins  G,  et al.  Nonalcoholic fatty liver disease among HIV-infected persons.  J Acquir Immune Defic Syndr. 2009;50(5):464-473.

5.Glesby  MJ, Albu  J, Chiu  YL,  et al.  Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.  PLoS One. 2013;8(4):e61160.

6.He  Q, Engelson  ES, Kotler  DP, Albu  JB, Chiu  YL, Glesby  MJ.  Effect of recombinant human growth hormone (rhGH) and rosiglitazone (rosi) on liver fat in people with HIV-associated abdominal obesity and insulin resistance. Abstract presented at: 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; Washington, DC; July 19-21, 2012. Abstract P10.

7.Falutz  J, Allas  S, Blot  K,  et al.  Metabolic effects of a growth hormone-releasing factor in patients with HIV.  N Engl J Med. 2007;357(23):2359-2370.

8.Falutz  J, Mamputu  JC, Potvin  D,  et al.  Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.  J Clin Endocrinol Metab. 2010;95(9):4291-4304.

9.Lemieux  S, Prud’homme  D, Bouchard  C, Tremblay  A, Després  JP.  A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue.  Am J Clin Nutr. 1996;64(5):685-693.